Eton Pharmaceuticals (ETON) Q3 2026 earnings review
Eton's new infant drug doubles sales, while pipeline trials slip
Eton Pharmaceuticals, a seller of rare-disease drugs, beat its own 2027 revenue goal five quarters early as its new infant tumor medicine scaled up. Third-quarter sales more than doubled to $58 million, and the Ebitda margin excluding one-offs reached 49% because the existing sales force carried the new volume. Chief executive Sean Brynjelsen raised the 2026 sales floor to $175 million, which by our math leaves a cautious $55 million floor for the fourth quarter.
| Revenue | $57.9M +158% from a year ago |
|---|---|
| Ebitda margin, excluding one-offs | 49% 13% a year ago |
| Profit per share, excluding one-offs | $0.50 $0.04 a year ago |
| Full-year revenue outlook | Raised $30M now >$175M (+119% from 2025) |
⚖️ Verdict: 🟢 Bullish
The story got better because the first full quarter of HEMANGEOL proved that Eton's commercial platform can absorb a major drug and turn nearly half of total sales into operating profit. Strong cash generation also lifted cash to $56 million, removing any strain from debt payments while funding a new neurology license. The bad news: Eton stopped giving specific patient counts, and weak pilot data for its Wilson disease candidate ET-700 will require new formulation tests in 2027.
The question now is how much of this $232 million annualized sales pace is durable past October 2028, when HEMANGEOL loses patent protection. One view is that follow-on gel ASN-001 and April's planned seizure-drug launch will replace and grow the franchise; the other is that hidden product sales mask reliance on a single expiring medicine while internal trials slip. Product disclosures in the quarterly filing and the March 2027 FDA decision on LIBERVANT will tell.
🐂 Bull Case
New Infant Drug Pushed Sales Past the 2027 Goal
Eton buys and sells treatments for rare pediatric conditions. In May it relaunched HEMANGEOL, an oral liquid for benign blood-vessel tumors in infants. Chief executive Sean Brynjelsen said third-quarter sales of $57.9 million "surpassed our $200 million annualized revenue run rate goal five quarters ahead of schedule".
This was the first full quarter of HEMANGEOL sales after Eton moved patients onto its support program. Total revenue jumped 54% from the second quarter and 158% from a year ago, even though last year's third quarter included $3.3 million of one-off international orders. That jump prompted management to raise its full-year sales floor by $30 million, to more than $175 million.
What to watch: fourth-quarter revenue against the $57.9 million third-quarter level. Because the new full-year floor requires only $55.2 million in the fourth quarter by our math, another sequential rise will show whether new infant starts are still growing after the initial patient transfer.
Existing Sales Team Carried the New Drugs
Eton's business model relies on adding acquired medicines to its existing specialist sales force and patient-support hub without adding many staff. That operating leverage showed up across every cost line in the third quarter.
- Gross margin excluding one-offs: 79.7%, up 34.4 percentage points from a year ago and 6.8 points from the second quarter
- Administrative and sales overhead excluding one-offs: 22.0% of revenue, down from 30.5% a year ago
- Research and development: 9.1% of revenue, up 4.2 percentage points because of a $3 million upfront licensing fee
- Ebitda margin excluding one-offs: 49.3%, up from 12.8% a year ago and 43.2% last quarter
Profitability rose even though the rare-disease drugmaker expensed the $3 million licensing payment for ASN-001, an experimental topical gel, inside research costs. Without that one-time payment, the Ebitda margin excluding one-offs would have reached 54.5% by our math, already above the company's long-term 50% goal.
What to watch: fourth-quarter gross margin excluding one-offs. Eton may owe a $4 million sales milestone for its adrenal drug ALKINDI SPRINKLE in the fourth quarter, which will test how well product mix holds up.
Operating Cash Flow Paid Down Debt and Funded Deals
A standing concern was that Eton's $23.1 million of debt and its pace of drug acquisitions would strain its cash balance. In the third quarter, the Illinois-based company generated $35.2 million of free cash flow by our math, more than double the $14.6 million it produced across the entire first half of the year.
That cash inflow allowed Eton to pay down $8 million of long-term debt during the first nine months and spend $18.2 million acquiring product rights, while still lifting cash on hand to $55.6 million. Cash now exceeds total debt by $32.6 million by our math, removing the risk that debt repayments in 2027 will crowd out new deals.
What to watch: fourth-quarter operating cash flow and accrued Medicaid rebates. Rebates owed to government programs rose only $0.3 million over the first nine months to $9.7 million, so a year-end catch-up payment could still cause a single-quarter cash dip.
Four Moves Expand the Portfolio Into Neurology
Eton relies on licensing deals to keep growing, and this quarter it added a new medical specialty. It licensed US rights to LIBERVANT, a dissolving cheek film for emergency epileptic seizures, which has a March 29, 2027 FDA decision date for children aged 6 to 11 and targets a US market Eton estimates at more than $450 million.
The company also began US shipments of IMPAVIDO, a treatment for a rare parasitic infection, in September. In its pipeline, it started a study for ASN-001 — which Eton says has the "potential to become the Company’s largest revenue-generating product, if approved" — and filed to test its growth-hormone drug INCRELEX for infant spasms under the name ET-900.
What to watch: the FDA decision on LIBERVANT on March 29, 2027. Approval for the 6-to-11 age group will allow Eton to launch the seizure film in April 2027 and prove it can sell outside endocrinology.
🐻 Bear Case
Product Sales Breakdowns Stay Hidden as Counts Drop
Brynjelsen said Eton achieved "record levels of active patients for all of our key products", naming six drugs including HEMANGEOL and INCRELEX. Yet the earnings release gave zero patient numbers and did not break out revenue for any single medicine.
In earlier quarters, management reported exact milestones, such as passing 600 active patients in its adrenal franchise in June and 300 on its Wilson disease drug GALZIN in March. It stopped sharing patient counts for INCRELEX earlier this year after growth slowed near 100 patients, and it has never disclosed what HEMANGEOL earns per patient.
Withholding product figures matters because HEMANGEOL drove almost the entire $20.3 million quarterly revenue jump. Without product sales or patient counts, investors cannot tell how much of the growth came from one-time patient transfers versus ongoing demand, or verify the net price Eton collects after free-drug programs.
What to watch: product revenue disclosures in the upcoming third-quarter 10-Q filing. If Eton still groups all twelve medicines into one line, the true run-rate of its largest drug ahead of its October 2028 patent expiry will remain unverifiable.
Pipeline Delays and Weak Trial Data Cloud 2028
To keep growing after HEMANGEOL loses patent protection in October 2028, Eton needs its internal clinical programs to succeed on time. This quarter brought setbacks to two of its main expansion projects, while a third remains months away from market.
- ET-700 (extended-release zinc for Wilson disease): cut liver copper uptake by 12% in a 12-patient pilot study, compared with a 46% reduction for Eton's existing drug GALZIN
- INCRELEX label expansion (to widen the US patient pool from 200 to 1,000): first patient dosing pushed to "in the coming months", the sixth delay in seven quarters
- KHINDIVI under-age-5 expansion (adrenal insufficiency): FDA review set for May 28, 2027, keeping wider adoption on hold until mid-2027
Because ET-700 blocked far less copper than GALZIN, Eton cannot start its pivotal trial in early 2027 as planned. Instead, it will run extra study arms in 2027 on faster-release versions to "seek to improve copper absorption inhibition while preserving favorable safety profile", pushing a potential launch further out.
What to watch: confirmation that the first patient has been dosed in the INCRELEX study, and the FDA filing for Glyburide Oral Suspension by early 2027. Further slips would leave Eton more dependent on buying outside drugs.
Risks This Quarter Didn't Answer
Three standing business risks received no update in the third-quarter earnings release.
- HEMANGEOL October 2028 patent expiry: the release gave no update on patent extensions or how quickly ASN-001 can replace HEMANGEOL before generic copies enter.
- Single pharmacy reliance: Eton ships roughly 90% of its medicines through one specialty pharmacy, AnovoRx; the 10-Q customer table will show whether that concentration held.
- International INCRELEX profitability: sales of INCRELEX and GALZIN outside the US fell to $1.2 million from $2.9 million in the second quarter, and the release did not say whether international shipments still lose money.
👓 Other Themes
Tax Credit Doubled Reported Profit as Regulatory Fees Rose
Because Eton is now consistently profitable, it released a valuation allowance on its federal and state tax assets, booking a one-time $12.9 million tax benefit that lifted reported net income to $35.2 million. Excluding one-offs, net income was $16.5 million. Separately, Eton's higher sales meant it lost its small-business regulatory waiver, leading to "higher FDA fees following the loss of eligibility for the orphan drug fee exemption".
💲 Other KPIs
Uncollected customer bills rose 102% from a year ago and more than doubled from $11.8 million at the end of 2025. Even so, receivables grew slower than the 158% jump in third-quarter revenue, which indicates that Eton's specialty pharmacy partner is paying on schedule as HEMANGEOL sales scale up.
Stock on hand fell 28% from $15.4 million at the end of 2025, though it rose slightly from $10.1 million in the second quarter. Working down the drug stock acquired in the INCRELEX and HEMANGEOL deals contributed $3.4 million to operating cash flow over the first nine months.
The diluted share count rose 6.8% from 31.1 million a year ago (on the basis used for profit excluding one-offs) and 1.5% from the second quarter. Employees exercised $5.8 million of stock options during the first nine months, and the higher share count slightly reduced per-share profit growth.
🔮 Guidance
Raised. Management lifted the full-year sales floor by $30 million, which points to at least 119% growth over 2025. It is the third raise this year, and each step has been larger than the last: +$10 million, +$25 million, and +$30 million. By our math, the $175 million floor leaves only $55.2 million for the fourth quarter, below the third quarter's $57.9 million.
Raised. Eton increased its full-year profit margin floor by 5 percentage points after reaching 49.3% in the third quarter and 42.1% across the first nine months. By our math, hitting a 40% margin on $175 million of sales allows the fourth-quarter margin to drop to 35.4%, giving the drugmaker room to absorb a potential $4 million milestone payment.
Unchanged. The company kept its full-year gross margin floor above 70% even though the third quarter reached 79.7% and the first nine months sit at 75.0% by our math. That leaves an implied fourth-quarter floor of just 59.2% on $175 million of revenue, showing how much cushion management left for fourth-quarter milestone costs.
❓ Key Questions
How much revenue did HEMANGEOL generate in the third quarter?
Total revenue rose $20.3 million from the second quarter during HEMANGEOL's first full period on the market. Without a product figure or the share of patients receiving free drug, investors cannot separate one-time transfer gains from ongoing demand.
Why did Eton stop reporting specific active patient counts?
Management previously shared patient milestones for its adrenal franchise, GALZIN, and INCRELEX, but gave none in this release despite claiming record counts across all six drugs. Specific numbers are needed to track growth in the older medicines.
How long will the ET-700 reformulation delay the pivotal trial?
ET-700 reduced liver copper by 12% versus 46% for GALZIN, forcing Eton to test faster-release versions in 2027 instead of starting a pivotal trial in early 2027. Management has not said when the pivotal trial will now begin.
Why has the INCRELEX study dosing slipped for six quarters?
Dosing the first patient to align US and European patient definitions moved from late 2026 to the coming months. Because this trial is meant to expand the US patient pool five-fold, repeated delays push out a major growth driver.